US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease - Extavia is branded version of interferon beta-1b, a ...
Swiss drug giant Novartis received a boost this morning in the form of a US approval to market the multiple sclerosis therapy Extavia, its own branded version of Bayer’s interferon beta-1b drug ...
Novartis' recent launch of Extavia in Europe may not significantly alter the multiple sclerosis landscape, but it points to the entrance of a formidable new player into the market. Extavia is ...
This one has blockbuster potential. Today, some good news and bad news for companies selling drugs to treat multiple sclerosis. Now, the good news. Extavia isn't likely to become a blockbuster, and ...
Novartis has launched its multiple sclerosis drug Extavia in Europe, its branded version of Bayer's multiple sclerosis drug Betaseron. Novartis has launched its multiple sclerosis drug Extavia in ...
Therapy will compete with Schering-Plough’s Betaseron. FDA approved Novartis’ Extavia®, a branded version of the multiple sclerosis drug, interferon beta-1b. FDA sanctioned the drug for the treatment ...
In anticipation of regulatory approval for a new multiple sclerosis drug, Novartis is building up market expertise in an unusual way: by selling a generic version of an older MS drug. Last week, the ...
EXTON, Pa., Jan. 11 BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December ...
The FINANCIAL — The US Food and Drug Administration (FDA) has approved Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results